ClinicalTrials.gov
public full text
Public Domain
Dopamine D3 Receptor Occupancy in Bipolar Depression
Bipolar disorder is a common condition that can cause significant disability and risk for suicide. Second generation antipsychotic medications can be used to treat depression in bipolar disorder, yet we do not know how they work. Here, we will use a recently approved medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will have brain imaging with PET scans before and during treatment to understand how the medication may be working. Particularly, we will look at the role of the D3 dopamine receptor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- D-serine Monotherapy for Schizophrenia#884301
- New Approaches to Cocaine Abuse Medications (A) - 6#801814
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder#1058862
- Aripiprazole as Augmentation for TRD#807363
- Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar Disorder#862573
Record · ID 813357
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive